welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: September 2012
estimated completion: August 2016
size / enrollment: 53
The purpose of this tissue bank is to collect blood and skin samples from participants who are diagnosed with Duchenne muscular dystrophy (DMD) and carry one of nine specific changes in the dystrophin gene. The specific dystrophin changes that we are interested in studying are those that would work with exon-skipping therapies in patients with DMD, specifically deletions of the follow exons: 10-52, 13-50, 29-50, 43-52, 44, 43-50, 45-50, 45-52, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-60, 47-50, 47-52, 48-50, 49-50, 50, 52, 52-63, 48-52, 49-52, 50-52.
These blood and skin samples will be held in a tissue bank at Carolinas Medical Center for future DMD research.
- Tissue Collection [ Time Frame: 1 day ]
Collection of blood, skin and optional muscle samples
• Age 4 and above
• Diagnosis of DMD with a confirmed out-of-frame dystrophin gene deletions that could be corrected by skipping exon 45, 51, or 53 based on past genetic testing.
exclusion criteria: Investigator assessment of inability to comply with blood and skin sample collection
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)This Phase IIb study is a randomized, do...
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-studyCarriers of Duchenne muscular dystrophy ...
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
Peak Cough Flow and Cough Clearance in Patients With Muscular DystrophyThis study is to determine whether physi...
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02This study, HALO-DMD-03, is a follow-on ...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
FDA grants RASRx1902 orphan drug status as potential therapy for Duchenne muscular dystrophyThe U.S. Food and Drug Administration ha...
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...
State-of-the-art advances in Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) is a s...